CTOs on the Move

WellDoc

www.welldoc.com

 
We`re making healthcare transformation personal. Driving down the cost of chronic conditions is going to take all of us. Welldoc is here to help with BlueStar, our in-app digital assistant for type 2 diabetes. Chronic with ease. Working together to redefine how engaging and personally transformative technology can be will lead to real change: starting and evolving habits, taking daily responsibility for our well-being, and moving outcomes and costs to a much more manageable place. Technology and teamwork. It`s time to make every moment, every action, every healthcare decision count.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.welldoc.com
  • 10221 Wincopin Circle Suite 150
    Columbia, MD USA 21044
  • Phone: 443.692.3100

Executives

Name Title Contact Details
Ken Brown
 Chief Information Security Officer Profile

Similar Companies

Iora Health

Iora Health is transforming health care, starting with primary care.

Soredex

Soredex is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

On Assignment, Inc.

On Assignment, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Standard Homeopathic Co (Hylands)

Standard Homeopathic Co (Hylands) is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Carson, CA. To find more information about Standard Homeopathic Co (Hylands), please visit www.hylands.com